BioSpace News Archive

Biotech Beach

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation ), a leader in molecular diagnostics and precision medicine, announced interim results from the AUSPREDICT registry.

October 30, 2022
·
7 min read
Drug Development

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Biologics, Inc. announced that the first patient was dosed in Australia for its proprietary anti-Claudin18.2 monoclonal antibody-drug conjugate in Phase I clinical trial for the treatment of patients with advanced solid tumors.

October 30, 2022
·
8 min read
Policy

Clinical Research Opportunities in China and the Path to USFDA Approval – Whitepaper

Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert guidance on pathways to USFDA approval for biotechs conducting research in China.

October 30, 2022
·
2 min read
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

Akeso, Biopharma released the Phase Ib clinical results of Ivonescimab in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer, in an oral presentation at the IASLC 2022 Asia Conference on Lung Cancer.

October 30, 2022
·
3 min read
Business

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the fourth quarter ended September 30, 2022.

October 30, 2022
·
8 min read